Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042989 · ClinicalTrials.gov registry record · Phase 1
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
A Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT02042989: Completed Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
NCT02042989 is a Phase 1 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 68 participants, roughly in line with the 63-participant average among 10 other Advanced Cancers trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02042989, a Phase 1 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
Primary Outcome
Maximum tolerated dose is the highest dose level in which 6 patients have been treated with at most 1 experiencing dose limiting toxicity (DLT). Dose-limiting toxicity defined if the events occur within the first cycle (28 days).
Conditions Studied
Interventions
- DRUG Vorinostat
- DRUG MLN9708
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-06-27 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 1 |
What the finished NCT02042989 record still lists
NCT02042989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, roughly in line with the 63-participant average among 10 other Advanced Cancers trials with a reported enrollment target.
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 2 interventions - of which Vorinostat is the first listed.
NCT02042989 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02042989 about?
NCT02042989 is a clinical study titled "MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
What is the current status of trial NCT02042989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-06-27. Estimated completion is 2020-01-22.
What conditions does trial NCT02042989 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT02042989?
The interventions under investigation include: Vorinostat (DRUG), MLN9708 (DRUG).
Who is sponsoring clinical trial NCT02042989?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02042989 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02042989's enrollment target sits among peer trials
68 4th of 10 higher than 7 of 10 other Advanced Cancers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Study of Vemurafenib, Carboplatin, and Paclitaxel
COMPLETED · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
-
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
COMPLETED · Phase 1
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI